A Study for Participants With Type 2 Diabetes Mellitus

Phase 2 Completed 87 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

This drug is being evaluated for possible treatment of type 2 diabetes mellitus. Participation in this study is expected to last up to 18 weeks. A goal of this study is to determine the safety and effectiveness of LY2409021.

Timeline

Start: 2009-03
Primary completion: 2010-02
Completion: 2010-02

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs 10 mg LY2409021; p = 0.0296; Mean Difference (Final Values) -0.94 (90% CI -1.64 to -0.23); Mixed Models Analysis NCT00871572 ↗

registry analysis (superiority or other test); Placebo vs 30 mg LY2409021; p = 0.0418; Mean Difference (Final Values) -0.76 (90% CI -1.37 to -0.15); Mixed Models Analysis NCT00871572 ↗

Publications

Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care. 2016 Jul;39(7):1241-9. doi: 10.2337/dc15-1643. Epub 2015 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADOMEGLIVANT	Small molecule	10 mg	Oral
Subject	ADOMEGLIVANT	Small molecule	30 mg	Oral
Subject	ADOMEGLIVANT	Small molecule	60 mg	Oral